MedTrace Logo

Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)

NCT00497484 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2007-07-06

No results posted yet for this study

Summary

We have recently demonstrated resistance to GHRH leading to GH deficiency in patients with Pseudohypoparathyroidism type Ia (Mantovani et al., J Clin Endocrinol Metab, 2003. 88: 4070-4074). The purpose of this study is to evaluate the effect of at least 1-year GH replacement in these patients. In particular, we will focus our attention on growth velocity in children affected with this disease.

Conditions

  • Pseudohypoparathyroidism
  • Growth Hormone Deficiency, Dwarfism

Interventions

DRUG

recombinant human somatotropin

Sponsors & Collaborators

Principal Investigators

  • Paolo Beck-Peccoz, MD/PhD · Endocrine Unit, Dpt. of Medical Sciences, Fondazione Policlinico IRCCS, Milan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00497484 on ClinicalTrials.gov